20109208

Source:http://linkedlifedata.com/resource/pubmed/id/20109208

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0005823, umls-concept:C0011860, umls-concept:C0018810, umls-concept:C0031928, umls-concept:C0034656, umls-concept:C0167117, umls-concept:C0332307, umls-concept:C0681850, umls-concept:C1280500, umls-concept:C1550501, umls-concept:C1706203, umls-concept:C2349001, umls-concept:C2697811
pubmed:dateCreated	2010-2-18
pubmed:databankReference	http://linkedlifedata.com/resource/pubmed/xref/ClinicalTrials.gov/NCT00516074
pubmed:abstractText	Cardiovascular effects of glucose-lowering agents are of increasing interest. Our aim was to assess the effects of the glucagon-like peptide-1 receptor agonist exenatide on heart rate (HR) and blood pressure (BP) in subjects with type 2 diabetes mellitus (T2DM).
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-10388979, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-10938049, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-11730979, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-11897280, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-12093887, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-12777949, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-12860201, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-12882864, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-12975389, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-15313949, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-15353407, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-15356213, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-15582729, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-16305055, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-16736131, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-17174230, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-17498508, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-18053320, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-18782641, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-18803987, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-19047364, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-19195607, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-19383034, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-8166268, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-9257113, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-9635947, http://linkedlifedata.com/resource/pubmed/commentcorrection/20109208-9831697
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101147637
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobin A, Glycosylated, http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Peptides, http://linkedlifedata.com/resource/pubmed/chemical/Placebos, http://linkedlifedata.com/resource/pubmed/chemical/Venoms, http://linkedlifedata.com/resource/pubmed/chemical/exenatide
pubmed:status	MEDLINE
pubmed:issn	1475-2840
pubmed:author	pubmed-author:BraunDanielD, pubmed-author:BruceSimonS, pubmed-author:BurgerJudeJ, pubmed-author:GiaconiaJosephJ, pubmed-author:GillAnneA, pubmed-author:HoogwerfByron JBJ, pubmed-author:MacconellLeighL, pubmed-author:MaloneJamesJ, pubmed-author:MortPP
pubmed:issnType	Electronic
pubmed:volume	9
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	6
pubmed:dateRevised	2010-9-28
pubmed:meshHeading	pubmed-meshheading:20109208-Blood Pressure, pubmed-meshheading:20109208-Body Weight, pubmed-meshheading:20109208-Diabetes Mellitus, Type 2, pubmed-meshheading:20109208-Double-Blind Method, pubmed-meshheading:20109208-Heart Rate, pubmed-meshheading:20109208-Hemoglobin A, Glycosylated, pubmed-meshheading:20109208-Humans, pubmed-meshheading:20109208-Hypoglycemic Agents, pubmed-meshheading:20109208-Monitoring, Ambulatory, pubmed-meshheading:20109208-Peptides, pubmed-meshheading:20109208-Pilot Projects, pubmed-meshheading:20109208-Placebos, pubmed-meshheading:20109208-Venoms
pubmed:year	2010
pubmed:articleTitle	Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study.
pubmed:affiliation	Eli Lilly and Company, Indianapolis, USA.
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study